Concord Biotech Limited

NSE CONCORDBIO.NS

Concord Biotech Limited Shareholders' Equity for the year ending March 31, 2024: USD 183.03 M

Concord Biotech Limited Shareholders' Equity is USD 183.03 M for the year ending March 31, 2024, a 16.61% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Concord Biotech Limited Shareholders' Equity for the year ending March 31, 2023 was USD 156.95 M, a 8.03% change year over year.
  • Concord Biotech Limited Shareholders' Equity for the year ending March 31, 2022 was USD 145.29 M, a 6.46% change year over year.
  • Concord Biotech Limited Shareholders' Equity for the year ending March 31, 2021 was USD 136.48 M, a 58.58% change year over year.
  • Concord Biotech Limited Shareholders' Equity for the year ending March 31, 2020 was USD 86.07 M.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
SV Wall Street
NSE: CONCORDBIO.NS

Concord Biotech Limited

CEO Mr. Ankur Vaid
IPO Date Aug. 18, 2023
Location India
Headquarters 16th Floor, B-Wing
Employees 1,377
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

StockViz Staff

February 6, 2025

Any question? Send us an email